NeuBase Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

NeuBase Therapeutics announced that CEO Dietrich A. Stephan, Ph.D., will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will take place on September 13 at 7:00 a.m. ET. NeuBase focuses on developing precision genetic medicines aimed at addressing genetic diseases.

Designed to modify gene function, their targeted PATrOL™ therapies are being developed to tackle neuromuscular, neurological, and oncologic disorders. Further details can be accessed through the company's website.

PITTSBURGH, Sept. 01, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual H.C. Wainwright 23rd Annual Global Investment Conference being held September 13 to 15.

H.C. Wainwright 23rd Annual Investment Conference
Date:	Monday, September 13th
Time:	7:00 a.m. ET
Location:	Webcast link or at the company’s website.

About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neuromuscular, neurological, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.

Investor Contact: 
Daniel Ferry 
LifeSci Advisors 
+1 617-430-7576 
daniel@lifesciadvisors.com 

NeuBase Media Information:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
(858) 344-8091
jessica@litldog.com 

FAQ

When will NeuBase present at the H.C. Wainwright 23rd Annual Global Investment Conference?

NeuBase Therapeutics will present on September 13, 2021, at 7:00 a.m. ET.

What is the focus of NeuBase's presentation at the conference?

The focus will be on a corporate overview and their efforts in developing precision genetic medicines.

Where can I watch the NeuBase presentation?

The presentation can be viewed via a webcast link or on the company's website.

What are PATrOL therapies developed by NeuBase?

PATrOL therapies are designed to modify gene function to address genetic defects in neuromuscular, neurological, and oncologic disorders.

What is the significance of September 15 for NeuBase?

September 15 marks the conclusion of the H.C. Wainwright 23rd Annual Global Investment Conference.